Market Capitalization (Millions $) |
1,743 |
Shares
Outstanding (Millions) |
62 |
Employees |
- |
Revenues (TTM) (Millions $) |
9 |
Net Income (TTM) (Millions $) |
-134 |
Cash Flow (TTM) (Millions $) |
-25 |
Capital Exp. (TTM) (Millions $) |
1 |
Ambrx Biopharma Inc
Ambrx Biopharma Inc is a biotechnology company focused on the development of innovative protein therapeutics. The company employs an advanced platform technology called Expanded Genetic Code, which allows for the incorporation of unnatural amino acids into proteins during their synthesis. This technology enables the creation of novel therapeutics with improved selectivity, potency, and pharmacokinetic properties.
Ambrx aims to address significant unmet medical needs by developing protein-based drugs for the treatment of various diseases, including cancer, metabolic disorders, and autoimmune diseases. The company collaborates with pharmaceutical partners to advance its pipeline of product candidates through preclinical and clinical development stages.
In addition to its proprietary pipeline, Ambrx also offers its Expanded Genetic Code technology to other pharmaceutical companies through collaborations and licensing agreements. This allows partners to develop their own customized protein therapeutics using the platform.
Overall, Ambrx Biopharma Inc is a biotech company utilizing a unique technology to develop innovative protein-based drugs that hold promise for improving patient care and addressing unmet medical needs.
Company Address: 10975 North Torrey Pines Road La Jolla 92037 CA
Company Phone Number: 875-2400 Stock Exchange / Ticker: NASDAQ AMAM
AMAM is expected to report next financial results on March 29, 2024. |
|
|